Long term data

Glucose control with the Inreda AP® in type 1 diabetes: three years of real-world data

Inreda®

Key findings

1. Time in range remained highly stable over three years (80-81%) in the GlucaGen-only group
2. Time below range ranged between 0.95 and 1.56% in a three-year period in the GlucaGen-only group
3. Glucose outcomes and treatment goal attainment deteriorated after the glucagon switch
4. Time in range decreased from 79.3 to 75.8% after the glucagon switch

Overview

This study was a retrospective, observational, real-world cohort study conducted over a three-year period in a home setting. The total population included 102 adults (18–75 years) with type 1 diabetes who used the Inreda AP® as regular care. A group of 60 Inreda AP® users were only treated with the initial glucagon (GlucaGen-only group), other users needed to switch to an alternative glucagon (Glugon) at some point during their treatment.

Results

80-81% TIR after 3 years

Time in range ranged from 80 to 81% in the GlucaGen-only group (A) and from 77 to 81% in the total group

54-57% TITR after 3 years

Time in tight range ranged from 54 to 57% in the GlucaGen-only group (A) and from 52 to 57% in the total group



- Time below range ranged from 0.95 to 1.56% in GlucaGen-only group (A) and from 1.03 to 1.69% in the total group
- All glucose outcomes significantly deteriorated switching from GlucaGen to Glugon

Conclusions

Real-world data demonstrated a stable long-term performance of the Inreda AP® in a three-year period in users who remained on GlucaGen. Overall study findings support long-term Inreda AP® treatment for maintaining adequate glycemic control in people with type 1 diabetes over several years.

Jansen, T., et al. (2026). Three-Year Real-World Performance of Bihormonal Fully Closed-Loop Therapy in Type 1 Diabetes. Diabetes Technology & Therapeutics. In press.

Inreda®

Long term data

Glucose control with the Inreda AP® in type 1 diabetes: three years of real-world data

= 102